title: Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
authors.forename: M Lynn
authors.initials: ML
authors.lastname: Crismon
authors.forename: Anthony
authors.initials: A
authors.lastname: DeLeon
authors.forename: Alexander L
authors.initials: AL
authors.lastname: Miller
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D000068180:Aripiprazole; D018491:Dopamine Agonists / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole